Skip to main content
HR 4106 116th Congress House Health Drug safety, medical device, and laboratory regulation Marketing and advertising Prescription drugs

Responsibility in Drug Advertising Act of 2019

Introduced: July 30, 2019 Introduced by: DeLauro, Rosa L. Democratic · Connecticut See on congress.gov
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 31, 2019
Referred to the Subcommittee on Health.
Jul 30, 2019
Referred to the House Committee on Energy and Commerce.
Jul 30, 2019
Introduced in House
 Plain-English summary Congressional Research Service

Responsibility in Drug Advertising Act of 2019

This bill prohibits direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.
What's happening now July 31, 2019

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2